Abstract
Cisplatin (CP) is an effective chemotherapeutic agent used in the treatment of a variety of solid tumours. The most frequently observed side-effect of the use of CP is nephrotoxicity. Recently, evidence has been demonstrated that reactive oxygen species forming in the tubular epithelium play an important role in CP-linked nephrotoxicity. The aim of the study was to observe the effect of hyperbaric oxygen (HBO) therapy on CP nephrotoxicity, a subject which has not been studied previously. Wistar rats were treated with CP (a single intraperitoneal (IP) dose of 0.6 mg/100 g) alone and in combination with HBO (60 min every day for seven days at 2.5×atmospheric pressure). Effects of the treatment on renal function and histology were determined. In analyses at the end of the study it was observed that serum urea, creatinine, and daily urinary protein excretion levels of the CP group were higher than at the start of the study, and that the creatinine clearance level had fallen (P<0.05). There was no significant difference between the CP+HBO group and HBO group serum urea, creatinine, creatinine clearance, and daily urinary protein excretion levels at the beginning and end of the study (P>0.05). Histopathological examination showed that the necrosis score in the proximal tubule epithelial cells and average apoptitic cell numbers in the CP group were higher than those in the CP+HBO and HBO groups (P<0.05). There was no statistical difference between the CP+HBO group and the HBO group in terms of necrosis score in the proximal tubule epithelial cells and the percentage of distal tubules containing hyaline casts in the lumen. In conclusion, in this study it was observed that in experimental study of CP nephrotoxicity the synchronous application of HBO therapy with CP prevents kidney damage.
Similar content being viewed by others
References
Appenroth D, Fröb S, Kertsen L, Splinter K, Winnefeld K (1997) Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol 71:677–683
Baliga R, Ueda N, Walker PD, Shah SV (1999) Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 31:971–997
Burkhart KK, Hall AH, Gerace R, Rumack BH (1991) Hyperbaric oxygen treatment for carbon tetrachloride poisoning. Drug Safety 6:332–338
Cameron JS, Greger R (1998) Renal function and testing of function. In: Davison AM, Cameron JS, Grünfeld JP, Kerr DNS, Ritz E, Winearls CG (eds) Oxford textbook of clinical nephrology, vol 1, China. Oxford Medical Publications, pp 39–69
Davis C, Nick H, Agarwal A (2001) Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 12:2683–2690
Hink J, Jansen E (2001) Are superoxide and/or hydrogen peroxide responsible for some of the beneficial effects of hyperbaric oxygen therapy? Med Hypotheses 57:764–769
Huang Y, Zhou S, Qui L, Wu J, Xu C (1997) Effects of zinc gluconate on nephrotoxicity and glutathione metabolism disorder induced by cisplatin in mice. Drug Metab Drug Interact 14:41–46
Jamieson D (1989) Oxygen toxicity and reactive oxygen metabolites in mammals. Free Radic Biol Med 7:87–108
Kruidering M, van de Water B, de Heer E, Mulder GJ, Nagelkerke JF (1997) Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 280:638–649
Kuhlmann MK, Burkhardt G, Köhler H (1997) Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12:2478–2480
Lebwohl D, Canetta R (1998) Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34:1522–1534
Nath KA, Norby SM (2000) Reactive oxygen species and acute renal failure. Am J Med 109:665–678
Nikkanen HE, Burns MM (2004) Severe hydrogen sulfide exposure in a working adolescent. Pediatrics 113:927–929
Özen S, Akyol Ö, Iraz M, Söğüt S, Özuğurlu F, Özyurt H, Odacı E, Yıldırım Z (2004) Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. J Appl Toxicol 24:27–35
Ramesh G, Reeves B (2004) Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-α. Kidney Int 65:490–498
Reiffenstein RJ, Hulbert WC, Roth SH (1992) Toxicology of hydrogen sulfide. Annu Rev Pharmacol Toxicol 32:109–134
Sadzuka Y, Shoji T, Takino Y (1992) Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem Pharmacol 43:1873–1875
Sahni T, Singh P, John MJ (2003) Hyperbaric oxygen therapy: current trends and applications. J Assoc Physicians India 51:280–284
Strauss MB, Bryant B (2002) Hyperbaric oxygen. Orthopedics 25:303–310
Thom SR, Elbuken ME (1991) Oxygen-dependent antagonism of lipid peroxidation. Free Radic Biol Med 10:413–426
Thom SR (1993) Functional inhibition of leukocyte B2 integrins by hyperbaric oxygen in carbon monoxide-mediated brain injury in rats. Toxicol Appl Pharmacol 123:248–256
Tibbles PM, Edelsberg JS (1996) Hyperbaric-oxygen therapy. N Engl J Med 334:1642–1648
Tomaszewski CA, Thom SR (1994) Use of hyperbaric oxygen in toxicology. Emerg Med Clin North Am 12:437–459
Ulubaş B, Çımen MYB, Apa DD, Saritaş E, Muşlu N, Çımen ÖB (2003) The protective effects of acetyl salicylic acid on free radical production in cisplatin induced nephrotoxicity: an experimental rat model. Drug Chem Toxicol 26:259–270
Weber LW, Boll M, Stampfl A (2003) Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 33:105–136
Zhang JG, Lindup WE (1993) Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 45:2215–2222
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Atasoyu, E.M., Yildiz, S., Bilgi, O. et al. Investigation of the role of hyperbaric oxygen therapy in cisplatin-induced nephrotoxicity in rats. Arch Toxicol 79, 289–293 (2005). https://doi.org/10.1007/s00204-004-0627-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-004-0627-3